Bringing science and development together through news and analysis

  • Turning the tide on malaria


Every year, a million children die from malaria — partly because ineffective antimalarial drugs continue to be used. But with strong and focused leadership the tide can be turned on this killer disease, says Nicholas White in this article.

The cheap antimalarial chloroquine has been the drug of choice for most developing nations over the past half century. Now, however, the drug is ineffective in many countries because the malaria parasite has developed a widespread resistance to it.

New results from a clinical trial in Malawi, which stopped using chloroquine in 1993, show that the drug can regain its potency if it is withdrawn from use (see Chloroquine works again, but scientists urge caution).

The drug would then be able to rejoin the queue of candidate antimalarial agents by being used in combination with other treatments, says White.

But first, he adds, effective alternatives — artemisinin-based combination treatments — must be made available in regions where malaria is endemic, at no more than 10 cents a day.

Richer countries will need to pay for this effort but it will not cost much, argues White: the tools to eradicate malaria are already available.

Link to full article in New England Journal of Medicine

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.